Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Off Label Drug Use Data To Be Required In Periodic Safety Updates - FDA

Executive Summary

Pharmaceutical companies will be asked to provide postmarketing drug usage information in their periodic safety update reports, including use in off label indications, under a proposed FDA rule due out later this year.
Advertisement

Related Content

FDA Plans Three Risk Management-Related Guidances Under PDUFA III
FDA Plans Three Risk Management-Related Guidances Under PDUFA III
Adverse Drug Event Monitoring Could Include Monthly Literature Reviews
Product Safety Update Report Burden Of Analysis Is On Sponsors, FDA Says
FDA Proposed Rule Will Require MedDRA for Postmarketing AE Reporting
Risk Management Assessments Will Be Part Of Advisory Committees - FDA
Proprietary Name Evaluation Guidance Will Detail New FDA Review Process
PhRMA Medication Error Reduction Plan Slated For July Release
FDA Post-Marketing Drug Risk Surveillance Requires More Funding, IG Says
FDA Post-Marketing Drug Risk Surveillance Requires More Funding, IG Says
Advertisement
UsernamePublicRestriction

Register

PS036313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel